ArticleCrohn's & colitis 3602025

Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials.

Bincy Abraham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.